To the Frontier
Beyond the
Cell Membrane.
With our proprietary
PepMetics® technology,
we bring new medicines
to patients.
The Frontier Beyond the
Cell Membrane
Within every cell, countless **protein–protein interactions (PPIs)** orchestrate the biological processes essential for life.
These interactions regulate cellular signaling, molecular transport, and many other critical functions.
When they become dysregulated, they can lead to a wide range of diseases.
For decades, researchers have sought to disrupt disease-causing PPIs inside cells by using molecules that mimic the interaction surfaces of proteins.
However, this has presented a fundamental challenge. Only **small molecules** can efficiently penetrate the cell membrane and reach intracellular targets.
Yet designing small molecules that faithfully mimic protein structures and bind with sufficient strength to block PPIs has proven extraordinarily difficult.
As a result, most intracellular PPIs have long remained an untapped frontier for drug discovery.
These interactions regulate cellular signaling, molecular transport, and many other critical functions.
When they become dysregulated, they can lead to a wide range of diseases.
For decades, researchers have sought to disrupt disease-causing PPIs inside cells by using molecules that mimic the interaction surfaces of proteins.
However, this has presented a fundamental challenge. Only **small molecules** can efficiently penetrate the cell membrane and reach intracellular targets.
Yet designing small molecules that faithfully mimic protein structures and bind with sufficient strength to block PPIs has proven extraordinarily difficult.
As a result, most intracellular PPIs have long remained an untapped frontier for drug discovery.
Delivering the Next Generation of
Medicines with PepMetics®
Beyond the cell membrane lies a vast frontier of therapeutic opportunity. **PepMetics®**, the proprietary drug discovery platform developed by PRISM BioLab, is designed to explore this frontier and continuously generate innovative medicines.
PepMetics® precisely reproduces the **α-helical structures** that are involved in approximately 60% of protein–protein interaction (PPI) interfaces.
By combining number of helix-mimicking scaffolds with diverse amino acid side chains, the platform enables the creation of billions of structurally diverse compounds.
This unique molecular design capability opens the door to discovering small molecules capable of disrupting disease-causing intracellular protein–protein interactions—targets that have long been considered beyond the reach of conventional drug discovery.
PepMetics® precisely reproduces the **α-helical structures** that are involved in approximately 60% of protein–protein interaction (PPI) interfaces.
By combining number of helix-mimicking scaffolds with diverse amino acid side chains, the platform enables the creation of billions of structurally diverse compounds.
This unique molecular design capability opens the door to discovering small molecules capable of disrupting disease-causing intracellular protein–protein interactions—targets that have long been considered beyond the reach of conventional drug discovery.
About us
Our team at PRISM BioLab works with pharmaceutical companies, biotech partners, and researchers to pioneer new frontiers in PPI-targeted drug discovery and deliver hope to patients worldwide.
Business model
In-house Pipelines:
PRISM selects drug discovery targets, originates programs, advances them toward clinical candidates, and out-licenses the resulting assets to pharmaceutical companies.
Platform Collaborations:
For targets of interest to our pharmaceutical partners, PRISM leverages PepMetics® Technology to discover and optimize compounds suitable for clinical development and out-licenses the resulting assets.
